American Journal of Endocannabinoid Medicine Examines Cannabis' Impact on COVID

The American Journal of Endocannabinoid Medicine (AEJM) is "the first and only American medical authority committed to the scientific study of the endocannabinoid system (ECS) and to the practice of evidence-based cannabinoid medicine."

AEJM has returned from COVID-19 hiatus and is distributing a new issue to more than 46,000 physicians. The latest edition of the AEJM will be 60 pages featuring:

• “The Complicated Relationship Between COVID-19 and Cannabis: A Year in Review” which examines how those who use medical cannabis may be at a higher risk of COVID-19 complications, while at the same time, medical cannabis shows some potential benefits to those exposed at certain stages of the virus. More research must and is being done.

• “Case Report: Cannabidiol in the Management of Acute Opioid Withdrawal” which shows that a 10-day regimen of high-dose, highly purified CBD successfully managed opioid withdrawal symptoms during the necessary wash-out period prior to the introduction of naltrexone for going abstinence maintenance therapy.

• “Cannabidiol as a Treatment for Behavioral Issues in Pediatric Patients With Intellectual Disabilities” which provides a review by Dr. Eric Exelbert of Joe DiMaggio Children’s Hospital of a recent study on whether “cannabidiol reduce severe behavioral problems in children with intellectual disability”.

"AJEM’s editors and contributors represent some of the country’s foremost experts on the effects of medical cannabis and the ECS in general. Currently, nearly 70% of the U.S. population live in states with legalized programs whose restrictions do not actively impede access to medical cannabis. Yet there are countless doctors who will not prescribe medical cannabis, even more who will not study its effects and millions of patients who cannot access it or are not willing to use it as medicine. AJEM aims to inform, educate and encourage doctors to better understand and better utilize ways and means to heal the endocannabinoid system," as reported by Insider New Jersey.

The organization's website states that the objective of the American Journal of Endocannabinoid Medicine is to help educate medical professionals on the role of the endocannabinoid system in homeostasis and as a therapeutic target.

The latest issue can be seen on the website. Some of the articles are available for review and download.